Logo image of PACS

PACS GROUP INC (PACS) Stock Fundamental Analysis

USA - NYSE:PACS - US69380Q1076 - Common Stock

13.07 USD
+1.1 (+9.19%)
Last: 9/22/2025, 2:59:41 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PACS. PACS was compared to 101 industry peers in the Health Care Providers & Services industry. PACS may be in some trouble as it scores bad on both profitability and health. PACS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

PACS had positive earnings in the past year.
PACS Yearly Net Income VS EBIT VS OCF VS FCFPACS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

PACS has a better Return On Assets (2.90%) than 63.37% of its industry peers.
PACS's Return On Equity of 19.73% is amongst the best of the industry. PACS outperforms 87.13% of its industry peers.
PACS has a Return On Invested Capital (4.38%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROIC 4.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PACS Yearly ROA, ROE, ROICPACS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 50 100 150 200

1.3 Margins

PACS has a Profit Margin of 3.63%. This is in the better half of the industry: PACS outperforms 70.30% of its industry peers.
With a decent Operating Margin value of 6.68%, PACS is doing good in the industry, outperforming 66.34% of the companies in the same industry.
The Gross Margin of PACS (21.33%) is comparable to the rest of the industry.
Industry RankSector Rank
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PACS Yearly Profit, Operating, Gross MarginsPACS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PACS is destroying value.
PACS has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for PACS is higher compared to a year ago.
PACS Yearly Shares OutstandingPACS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 50M 100M
PACS Yearly Total Debt VS Total AssetsPACS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 1.45, we must say that PACS is in the distress zone and has some risk of bankruptcy.
PACS has a worse Altman-Z score (1.45) than 64.36% of its industry peers.
PACS has a Debt/Equity ratio of 0.90. This is a neutral value indicating PACS is somewhat dependend on debt financing.
PACS has a worse Debt to Equity ratio (0.90) than 61.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 1.45
ROIC/WACC0.5
WACC8.71%
PACS Yearly LT Debt VS Equity VS FCFPACS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 1.71 indicates that PACS should not have too much problems paying its short term obligations.
The Current ratio of PACS (1.71) is comparable to the rest of the industry.
PACS has a Quick Ratio of 1.71. This is a normal value and indicates that PACS is financially healthy and should not expect problems in meeting its short term obligations.
PACS has a Quick ratio of 1.71. This is in the better half of the industry: PACS outperforms 62.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
PACS Yearly Current Assets VS Current LiabilitesPACS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for PACS have decreased strongly by -25.00% in the last year.
PACS shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.47%.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%

3.2 Future

The Earnings Per Share is expected to grow by 37.45% on average over the next years. This is a very strong growth
PACS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.92% yearly.
EPS Next Y92.3%
EPS Next 2Y46.69%
EPS Next 3Y37.45%
EPS Next 5YN/A
Revenue Next Year28.62%
Revenue Next 2Y22.64%
Revenue Next 3Y18.92%
Revenue Next 5YN/A

3.3 Evolution

PACS Yearly Revenue VS EstimatesPACS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B 5B
PACS Yearly EPS VS EstimatesPACS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0.5 1 1.5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 17.20, which indicates a rather expensive current valuation of PACS.
PACS's Price/Earnings ratio is rather cheap when compared to the industry. PACS is cheaper than 80.20% of the companies in the same industry.
PACS is valuated rather cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
PACS is valuated cheaply with a Price/Forward Earnings ratio of 7.95.
PACS's Price/Forward Earnings ratio is rather cheap when compared to the industry. PACS is cheaper than 96.04% of the companies in the same industry.
PACS is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 17.2
Fwd PE 7.95
PACS Price Earnings VS Forward Price EarningsPACS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PACS is valued a bit cheaper than 71.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.92
PACS Per share dataPACS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

PACS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PACS's earnings are expected to grow with 37.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.19
PEG (5Y)N/A
EPS Next 2Y46.69%
EPS Next 3Y37.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PACS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACS GROUP INC

NYSE:PACS (9/22/2025, 2:59:41 PM)

13.07

+1.1 (+9.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners29.43%
Inst Owner Change0.03%
Ins Owners71.98%
Ins Owner Change-0.49%
Market Cap2.03B
Analysts83.64
Price Target33.66 (157.54%)
Short Float %5.97%
Short Ratio3.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.28%
Min EPS beat(2)24.18%
Max EPS beat(2)56.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.83%
Min Revenue beat(2)2.62%
Max Revenue beat(2)5.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.07%
PT rev (3m)-4.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.41%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE 17.2
Fwd PE 7.95
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B 3.55
P/tB 4
EV/EBITDA 9.92
EPS(TTM)0.76
EY5.81%
EPS(NY)1.64
Fwd EY12.58%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS20.05
BVpS3.69
TBVpS3.27
PEG (NY)0.19
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROCE 6.06%
ROIC 4.38%
ROICexc 4.47%
ROICexgc 4.56%
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA 2.21
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z 1.45
F-ScoreN/A
WACC8.71%
ROIC/WACC0.5
Cap/Depr(3y)671.95%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
EPS Next Y92.3%
EPS Next 2Y46.69%
EPS Next 3Y37.45%
EPS Next 5YN/A
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%
Revenue Next Year28.62%
Revenue Next 2Y22.64%
Revenue Next 3Y18.92%
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.13%
EBIT Next 3Y32.1%
EBIT Next 5YN/A
FCF growth 1Y-74.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.22%
OCF growth 3YN/A
OCF growth 5YN/A